Trial Profile
A Safety, Tolerability, and Efficacy Study of LY2590443 in the Treatment of Acute Migraine Headache.
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 20 May 2020
Price :
$35
*
At a glance
- Drugs LY 2590443 (Primary) ; Sumatriptan
- Indications Migraine
- Focus Therapeutic Use
- 09 Dec 2009 Status changed from completed to discontinued as reported by ClinicalTrials.gov.
- 09 Sep 2009 Actual patient number (120) added as reported by ClinicalTrials.gov.
- 09 Sep 2009 Actual end date (May 2009) added as reported by ClinicalTrials.gov.